Evolent Health Inc. (EVH) Stock Rating Lowered by Zacks Investment Research
Evolent Health Inc. (NYSE:EVH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Monday.
According to Zacks, “Evolent Health, Inc. is involved in the healthcare delivery and payment markets. The company provides technology-enabled services platform for providers to transition their organization in value-based payment models. Evolent Health, Inc. is based in Arlington, Virginia. “
A number of other equities research analysts have also recently commented on EVH. Leerink Swann reiterated an “outperform” rating and set a $20.00 target price on shares of Evolent Health in a report on Sunday, July 17th. Jefferies Group initiated coverage on Evolent Health in a report on Tuesday, July 26th. They set a “buy” rating and a $28.00 price objective on the stock. FBR & Co raised their price objective on Evolent Health from $24.00 to $26.00 and gave the stock an “outperform” rating in a report on Friday, August 5th. Canaccord Genuity restated a “buy” rating and set a $30.00 price objective on shares of Evolent Health in a report on Sunday, August 7th. Finally, William Blair restated an “outperform” rating on shares of Evolent Health in a report on Friday, September 30th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Evolent Health presently has a consensus rating of “Buy” and a consensus target price of $27.17.
Shares of Evolent Health (NYSE:EVH) opened at 16.65 on Monday. The company has a 50 day moving average price of $22.08 and a 200 day moving average price of $20.43. The stock’s market cap is $1.13 billion. Evolent Health has a 12-month low of $8.14 and a 12-month high of $26.84.
Evolent Health (NYSE:EVH) last announced its earnings results on Wednesday, November 9th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. The firm had revenue of $60.20 million for the quarter, compared to analysts’ expectations of $58.35 million. Evolent Health had a negative return on equity of 5.54% and a negative net margin of 69.04%. Evolent Health’s quarterly revenue was up 39.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.16) EPS. Analysts anticipate that Evolent Health will post ($0.57) earnings per share for the current fiscal year.
In other news, COO Thomas Peterson III sold 72,827 shares of Evolent Health stock in a transaction dated Wednesday, September 14th. The stock was sold at an average price of $21.54, for a total transaction of $1,568,693.58. Following the sale, the chief operating officer now directly owns 377,623 shares of the company’s stock, valued at $8,133,999.42. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Board Co Advisory sold 1,936,529 shares of Evolent Health stock in a transaction dated Wednesday, September 14th. The stock was sold at an average price of $22.50, for a total value of $43,571,902.50. Following the sale, the insider now directly owns 4,445,879 shares in the company, valued at $100,032,277.50. The disclosure for this sale can be found here. Insiders own 8.85% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System raised its stake in shares of Evolent Health by 0.9% in the third quarter. California State Teachers Retirement System now owns 32,215 shares of the company’s stock worth $793,000 after buying an additional 300 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in Evolent Health by 1.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 42,784 shares of the company’s stock worth $822,000 after buying an additional 504 shares during the period. Rhumbline Advisers increased its position in Evolent Health by 4.0% in the third quarter. Rhumbline Advisers now owns 16,657 shares of the company’s stock worth $410,000 after buying an additional 640 shares during the period. Nationwide Fund Advisors increased its position in Evolent Health by 8.5% in the second quarter. Nationwide Fund Advisors now owns 10,109 shares of the company’s stock worth $194,000 after buying an additional 789 shares during the period. Finally, UBS Asset Management Americas Inc. increased its position in Evolent Health by 5.6% in the third quarter. UBS Asset Management Americas Inc. now owns 15,000 shares of the company’s stock worth $369,000 after buying an additional 800 shares during the period. 42.04% of the stock is currently owned by institutional investors and hedge funds.
Evolent Health Company Profile
Evolent Health, Inc supports integrated health systems in their migration towards value-based care and population health management. The Company’s services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services and health plan administration services.
Receive News & Stock Ratings for Evolent Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc. and related stocks with our FREE daily email newsletter.